Last reviewed · How we verify
Lansoprzole+Amoxicillin+Clarithromycin
This triple-therapy combination eradicates Helicobacter pylori by suppressing gastric acid (lansoprazole) while simultaneously killing the bacteria with two antibiotics (amoxicillin and clarithromycin).
This triple-therapy combination eradicates Helicobacter pylori by suppressing gastric acid (lansoprazole) while simultaneously killing the bacteria with two antibiotics (amoxicillin and clarithromycin). Used for Helicobacter pylori infection eradication in peptic ulcer disease, H. pylori-associated gastritis.
At a glance
| Generic name | Lansoprzole+Amoxicillin+Clarithromycin |
|---|---|
| Sponsor | Korean College of Helicobacter and Upper Gastrointestinal Research |
| Drug class | Proton pump inhibitor + antibiotic combination (triple therapy) |
| Target | H+ ATPase (lansoprazole); bacterial cell wall and protein synthesis (amoxicillin and clarithromycin) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion, creating an environment where antibiotics are more effective. Amoxicillin and clarithromycin are bactericidal and bacteriostatic antibiotics, respectively, that target H. pylori cell wall and protein synthesis. Together, this triple therapy achieves high eradication rates by combining acid suppression with dual antibiotic coverage.
Approved indications
- Helicobacter pylori infection eradication in peptic ulcer disease
- H. pylori-associated gastritis
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Taste disturbance
- Headache
- Allergic reactions (amoxicillin)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: